Literature DB >> 7049027

Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy.

R P Hall, T J Lawley, H R Smith, S I Katz.   

Abstract

Four patients with systemic lupus erythematosus developed a nonpruritic vesiculobullous eruption that was unresponsive to high-dose systemic corticosteroid therapy. In three patients the eruption was not associated with a flare of systemic disease. Biopsy results showed neutrophilic microabscesses at the dermal papillary tips and perivascular lymphohistiocytic infiltrates. Direct immunofluorescence of normal appearing skin not exposed to the sun was positive in all four patients. Due to the unresponsiveness to corticosteroid therapy and the striking histologic resemblance to dermatitis herpetiformis, each of the patients was treated with dapsone. Within 24 hours each patient had prompt cessation of the appearance of new lesions. Improvement of the eruption did not correlate with improvement of the systemic manifestations of their lupus erythematosus. The rapid response to dapsone therapy suggests that dapsone is useful in treating bullous lesions of systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7049027     DOI: 10.7326/0003-4819-97-2-165

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  20 in total

1.  Autoantibodies to type VII collagen have heterogeneous subclass and light chain compositions and their complement-activating capacities do not correlate with the inflammatory clinical phenotype.

Authors:  K Gandhi; M Chen; S Aasi; J C Lapiere; D T Woodley; L S Chan
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  [Vesicle, light hypersensitivity, mouth ulceration and arthralgia in a 40-year-old patient. Bullous systemic lupus erythematosus].

Authors:  A Kolb-Mäurer; S Herzog; C Sitaru; C Kneitz; D Zillikens; M Goebeler
Journal:  Hautarzt       Date:  2002-03       Impact factor: 0.751

Review 3.  The Cutaneous Spectrum of Lupus Erythematosus.

Authors:  Simone Ribero; Savino Sciascia; Luca Borradori; Dan Lipsker
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

4.  Vesiculobullous eruption in systemic lupus erythematosus: demonstration of common anti-DNA antibody idiotype at the dermo-epidermal junction.

Authors:  J A Miller; P M Dowd; C Dudeney; D A Isenberg
Journal:  J R Soc Med       Date:  1986-06       Impact factor: 5.344

Review 5.  Dapsone in the management of autoimmune bullous diseases.

Authors:  Evan W Piette; Victoria P Werth
Journal:  Dermatol Clin       Date:  2011-10       Impact factor: 3.478

6.  Bullous lesions as a manifestation of systemic lupus erythematosus in two Mexican teenagers.

Authors:  Marimar Sáez-de-Ocariz; Francisco Espinosa-Rosales; Eduardo López-Corella; Beatriz de León-Bojorge
Journal:  Pediatr Rheumatol Online J       Date:  2010-07-08       Impact factor: 3.054

7.  Studies of human C5a as a mediator of inflammation in normal human skin.

Authors:  K B Yancey; C H Hammer; L Harvath; L Renfer; M M Frank; T J Lawley
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

8.  Drug usage evaluation of dapsone.

Authors:  G Kannan; J Vasantha; N Vanitha Rani; P Thennarasu; K Kousalya; P Anuradha; C Umamaheswara Reddy
Journal:  Indian J Pharm Sci       Date:  2009-07       Impact factor: 0.975

9.  [Cutaneous lupus erythematosus. Part 2: diagnostics and therapy].

Authors:  A Kuhn; K Gensch; S Ständer; G Bonsmann
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

10.  [Bullous systemic lupus erythematosus].

Authors:  D Bacman; B Ostendorf; M Megahed; T Ruzicka; M Schneider; A Kuhn
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.